PRIVACY & TERMS

Johnson, Marcou & Isaacs, LLC ("JMI") will collect names and email addresses from its visitors to be used solely to respond to questions regarding the services we offer and/or general intellectual property questions.  All personal data received (names and email addresses) shall be considered confidential and will never be sold to third parties.

© 2019 Johnson, Marcou & Isaacs, LLC

  • LinkedIn Social Icon
SPECIALTY AREAS
 

Biochemistry

 

Biology

Biomedical Science

Cancer Biology

Chemistry

Genetics

Immunology

Medical Devices

Microbiology

Microfluidics

Molecular Biology

Molecular Genetics

Nanotechnology

Neuroscience

Organic Chemistry

Pharmaceuticals

Pharmacology

Physiology

Stem Cell Biology

Xiaoban Xin, J.D., Ph.D.

Associate

Dr. Xiaoban Xin, a registered U.S. patent attorney at Johnson, Marcou & Isaacs LLC (JMI), has a background in biotechnology and is fluent in Mandarin Chinese. He has experience preparing and prosecuting patent applications, patent portfolio management, strategic patent counseling, and due diligence. 

 

Previously, Dr. Xin was an associate at Bookoff McAndrews PLLC in Washington, D.C., and before that, he was a patent agent/associate with Wilson Sonsini Goodrich & Rosati PC in Washington, D.C. He was responsible for patent prosecution in the fields of biotechnology, including gene editing, next generation sequencing, precision medicine, biomarkers, stem cells, genetically modified animals, biologics, and pharmaceutical formulations, as well as medical device and health IT. 

 

Prior to his the legal career, Dr. Xin was a Technology Transfer Fellow at The National Institute of Allergy and Infectious Diseases (NIAID) at the National Institutes of Health (NIH). He has extensive laboratory experience as a biomedical researcher at The Johns Hopkins University School of Medicine, The University of Texas Health Science Center and Oklahoma State University. He also had the opportunity to have a pre-doctorial fellowship with the American Heart Association.

 

Dr. Xin obtained his juris doctorate at George Washington University Law School in Washington, D.C. He earned a doctorate in Biomedical Sciences (Cellular and Molecular Biology) from the University of Texas Health Science Center at San Antonio, and a bachelor of science in Biological Sciences at Nanjing University in China. 

 

Publications

  • Xin X "Patent Eligibility of 3D-Printed Organs," AIPLA Quarterly Journal, Vol. 44, No. 1, 2016 

  • Tan Y, Xin X. Coffey FJ, Wiest DL, Dong LQ, Testa JR. Appl1 and Appl2 are Expendable for Mouse Development But Are Essential for HGF-Induced Akt Activation and Migration in Mouse Embryonic Fibroblasts. J Cell Physiol.(2016) 231 (5):1142-50. 

  • Babapoor-Farrokhran S, Jee K, Puchner B, Hassan SJ, Xin X. et al. Angiopoietin-like 4 is a potent angiogenic factor and a novel therapeutic target for patients with proliferative diabetic retinopathy. Proc Natl Acad Sci USA.(2015) 112(23):E3030-9. 

  • Ryu J, Galan AK, Xin X. et al. APPL1 potentiates insulin sensitivity by facilitating the binding of IRS1/2 to the insulin receptor. Cell Rep.(2014) 7(4): 1227-38. 

  • Krispel C, Rodrigues M, Xin X. Sodhi A. Ranibizumab in diabetic macular edema. World J Diabetes.(2013) 4(6): 310-8. 

  • Xin X, Rodrigues M, Umapathi M et al. Up-regulation of Angiopoietin-like 4 Promotes Vascular Permeability in Ischemic Retinal Disease. Proc. Nad. Acad. Sci USA.(2013) 110(36): E3425-34. 

  • Rodrigues M, Xin X. et al. VEGF Secreted by Hypoxic Miiller Cells Induces MMP-2 Expression and Activity in Endothelial Cells to Promote Retinal Neovascularization in Proliferative Diabetic Retinopathy. Diabetes.(2013) 62(ll):3863-73. 

  • Xin X. Zhou L, Reyes CM, Liu F, Dong LQ. APPL1 mediates adiponectin-stimulated p38 MAPK activation by scaffolding the TAKl-MKK3-p38 MAPK pathway. Am. J. Physiol. Endocrinol. Metab. (2011) 300(1): E103-10 

  • Wang C, Xin X. Xiang R, Ramos FJ, Liu M, Lee HJ, Chen H, Mao X, Kikani CK, Liu F, and Dong LQ. Yin-Yang regulation of adiponectin signaling by APPL isoforms in muscle cells. /. Biol. Chem., (2009) 284(46): 31608-31615 

  • Wang C, Liu M, Riojas RA, Xin X. Gao Z, Zeng R, Wu J, Dong LQ, and Liu F. PKC(theta)-dependent phosphorylation of PDK1 at SER504 and SER532 contributes to palmitate-induced insulin resistance. J. Biol. Chem.(2009) 284(4): 2038-2044. 

  • Liu M, Zhou L, Xu A, Lam KS, Wetzel MD, Xiang R, Zhang J, Xin X. Dong LQ, and Liu F. A disulfide- bond A oxidoreductase-like protein (DsbA-L) regulates adiponectin multimerization. Proc. Nad. Acad. Sci. USA.(2008) 105(47): 18302-18307. 

  • Chen T, Cui J, Liang Y, Xin X. Owen Young D, Chen and C, Shen P. Identification of human liver mitochondrial aldehyde dehydrogenase as a potential target for microcystin-LR. Toxicology.(2006) 220(1): 71-80. 

  • Zhao SW, Shen PP, Zhou Y, Wei Y, Xin XB. and Hua ZC. (2005) Selecting peptide ligands of microcystin- LR from phage displayed random libraries. Environ. Int.31(4): 535-541. 

 

Education

  • J.D., George Washington University Law School, 2016

  • Ph.D., Biomedical Sciences (Cellular and Molecular Biology), University of Texas Health Science Center, 2011

  • B.S., Biological Sciences, Nanjing University, China, 2004

  • Editor, American Intellectual Property Law Association Quarterly Journal (AIPLA)

 

Admitted to Practice

  • United States Patent and Trademark Office

  • Maryland and District of Columbia Bars

Email:   xxin@jmi-iplaw.com

Direct:  301.313.0030

Please reload